Review article

https://doi.org/10.1515/acph-2017-0007

The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver diseases

XIN SUN ; Department of Pharmacy, Wuxi No. 2 People´sa Hospital, The Affiliated Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, China
YAN ZHANG ; Department of Gynecology and Obstetrics, Wuxi Maternal and Child Health Hospital, The Affiliated Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, China
MEILIN XIE ; Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, 215123, China

Abstract

Non-alcoholic fatty liver disease (NAFLD) has been defined as a spectrum of histological abnormalities and is characterized by significant and excessive accumulation of triglycerides in the hepatocytes in patients without alcohol consumption or other diseases. Current studies are targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. Many therapeutic targets have been found and used in clinical studies. Peroxisome proliferator-activated receptors (PPARs) are among the potential targets and have been demonstrated to exert a pivotal role in modulation of NAFLD. Many drugs developed so far are targeted at PPARs. Thus, the aim of this paper is to summarize the roles of PPARs in the treatment of NAFLD.

Keywords

non-alcoholic fatty liver disease; peroxisome proliferator-activated receptors; agonists; insulin resistance; inflammation

Hrčak ID:

167673

URI

https://hrcak.srce.hr/167673

Publication date:

31.3.2017.

Visits: 1.798 *